SXTP

+ Watchlist + Portfolio

60 Degrees Pharmaceuticals, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.25
52-Week Range: $0.84 – $8.62
Market Cap: $4.89M
P/E (TTM): —
EPS (TTM): -5.34
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -332.85%
Return on Assets: -127.11%
Gross Margin: -169.87%
Operating Margin: -1092.41%
Profit Margin: 0.00%
Current Ratio: 2.33
Debt/Equity: 0.06
Total Debt: $151.18K
Free Cash Flow: $-6.08M
Revenue Growth: -32.50%
Earnings Growth: —
Enterprise Value: $13.50M

SXTP Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$223.21K	$253.57K	$607.57K	$1.01M
Cost of Revenue	$432.37K	$474.55K	$384.76K	$781.70K
Gross Profit	-$209.16K	-$220.98K	$222.81K	$223.78K
Research & Development	$525.56K	$691.77K	$4.99M	$2.11M
Selling, General & Admin	$1.30M	$4.24M	$5.03M	$6.28M
Operating Expenses	$1.54M	$4.93M	$9.94M	$7.98M
Operating Income	-$1.75M	-$5.15M	-$9.72M	-$7.76M
EBITDA	-$2.11M	-$1.43M	-$7.88M	-$7.28M
Pretax Income	-$6.18M	-$3.81M	-$7.96M	-$7.37M
Income Tax	$500.00	$250.00	$0.00	$0.00
Net Income	-$6.18M	-$3.77M	-$7.95M	-$7.37M
Diluted EPS	-266.38	-236.72	-74.17	-11.73
Diluted Shares	23206	16578	113665	670211

SXTP Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$264.87K	$2.14M	$1.66M	$1.51M
Receivables	$45.97K	$231.33K	$486.75K	$509.64K
Inventory	$518.58K	$466.17K	$442.76K	$656.92K
Current Assets	$1.10M	$7.24M	$5.39M	$4.90M
Total Assets	$1.30M	$7.78M	$5.76M	$5.37M
Current Liabilities	$23.92M	$2.84M	$1.66M	$1.84M
Long-Term Debt	$1.27M	$150.25K	$147.12K	$144.00K
Total Debt	$22.42M	$172.67K	$155.89K	$152.78K
Total Liabilities	$25.45M	$2.99M	$1.80M	$1.99M
Retained Earnings	-$28.82M	-$32.58M	-$40.53M	-$47.89M
Shareholders' Equity	-$23.58M	$4.87M	$4.04M	$3.46M
Working Capital	-$22.82M	$4.41M	$3.73M	$3.05M
Net Debt	$22.14M	—	—	—

SXTP Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$1.01M	-$4.54M	-$5.65M	-$6.85M
Capital Expenditure	-$60.13K	-$115.89K	-$181.11K	-$218.08K
Free Cash Flow	-$1.07M	-$4.66M	-$5.83M	-$7.07M
Depreciation & Amortisation	$78.79K	$100.37K	$63.74K	$82.87K
Stock-Based Compensation	$0.00	$1.74M	$3.61M	$456.34K
Investing Cash Flow	-$60.13K	-$115.89K	-$1.89M	$254.92K
Financing Cash Flow	$1.22M	$6.47M	$7.05M	$6.44M
Net Change in Cash	$151.59K	$1.82M	-$483.63K	-$156.41K

SXTP Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$163.55K	$100.93K	$437.60K	$303.38K	$162.09K	$207.90K
Cost of Revenue	$73.27K	$50.05K	$537.69K	$120.68K	$85.72K	$151.10K
Gross Profit	$90.28K	$50.88K	-$100.09K	$182.70K	$76.38K	$56.80K
Research & Development	$370.81K	$231.91K	$809.78K	$638.87K	$281.46K	$598.65K
Selling, General & Admin	$1.72M	$1.63M	$1.51M	$1.47M	$1.89M	$1.73M
Operating Expenses	$2.00M	$1.66M	$2.23M	$2.10M	$2.17M	$2.33M
Operating Income	-$1.91M	-$1.61M	-$2.33M	-$1.92M	-$2.09M	-$2.27M
EBITDA	-$1.86M	-$1.71M	-$2.29M	-$1.41M	-$2.06M	-$2.23M
Pretax Income	-$1.88M	-$1.73M	-$2.32M	-$1.44M	-$2.09M	-$2.27M
Income Tax	$0.00	$0.00	$250.00	-$1.81K	$0.00	$0.00
Net Income	-$1.88M	-$1.73M	-$2.32M	-$1.44M	-$2.09M	-$2.26M
Diluted EPS	-6.25	-5.01	-2.52	—	-1.28	-0.90
Diluted Shares	320890	368250	918851	—	1.73M	2.65M

SXTP Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$3.45M	$1.97M	$4.12M	$1.51M	$3.34M	$1.02M
Receivables	$488.24K	$295.03K	$674.04K	$509.64K	$335.84K	$567.04K
Inventory	$773.24K	$799.42K	$527.00K	$656.92K	$910.60K	$877.95K
Current Assets	$5.65M	$3.84M	$6.31M	$4.90M	$6.26M	$3.73M
Total Assets	$5.98M	$4.18M	$6.69M	$5.37M	$6.76M	$4.28M
Current Liabilities	$1.80M	$1.69M	$2.20M	$1.84M	$1.88M	$1.61M
Long-Term Debt	$146.50K	$145.48K	$144.99K	$144.00K	$143.20K	$149.18K
Total Debt	$155.27K	$154.25K	$153.76K	$152.78K	$151.97K	$151.18K
Total Liabilities	$1.95M	$1.84M	$2.34M	$1.99M	$2.02M	$1.75M
Retained Earnings	-$42.40M	-$44.14M	-$46.45M	-$47.89M	-$49.98M	-$52.25M
Shareholders' Equity	$4.11M	$2.43M	$4.43M	$3.46M	$4.83M	$2.61M
Working Capital	$3.85M	$2.15M	$4.11M	$3.05M	$4.38M	$2.13M

SXTP Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$1.60M	-$1.45M	-$2.11M	-$1.69M	-$2.74M	-$2.23M
Capital Expenditure	-$5.48K	-$51.68K	-$25.49K	-$135.43K	-$41.44K	-$85.98K
Free Cash Flow	-$1.60M	-$1.50M	-$2.13M	-$1.83M	-$2.78M	-$2.32M
Depreciation & Amortisation	$16.80K	$19.68K	$22.83K	$23.57K	$25.86K	$30.81K
Stock-Based Compensation	$186.76K	-$9.62K	$167.24K	$111.96K	$124.10K	$2.40K
Investing Cash Flow	$1.70M	-$51.68K	-$25.49K	-$1.37M	$1.19M	-$85.98K
Financing Cash Flow	$1.70M	$0.00	$4.28M	$458.61K	$3.37M	$0.00
Net Change in Cash	$1.80M	-$1.50M	$2.15M	-$2.60M	$1.82M	-$2.32M

Market Snapshot

About

60 Degrees Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for the treatment and prevention of infectious diseases. The company is advancing tafenoquine, an 8-aminoquinoline antimalarial drug, for malaria prevention in travelers and military personnel. It leverages partnerships to develop and commercialize its product candidates.